NASDAQ-GS · traded in Congress
BridgeBio Pharma, BBIO
$77.69 +3.40 (+4.58%) Nov 9, 2026 4:25 AM ET
Market value$15.1B
P/E ratio-
Analyst target$108.00
52-week range-
Avg volume2,719,045
Dividend yieldN/A
Chart
Analyst ratings
- 20 buy
- 3 hold
- 0 sell
Low target$88.00
Average target$109.56
High target$156.00
Quarterly financials
| Quarter ended | Revenue | Gross profit | Net income | Net margin |
|---|---|---|---|---|
| $353M | - | $-57M | -16.1% | |
| $244M | - | - | - | |
| $195M | - | - | - | |
| $154M | - | - | - |
Congress trades in BBIO
Members of Congress disclosed 6 transactions in BBIO in the filings we have processed.
| Traded | Member | Type | Amount | Filed |
|---|---|---|---|---|
| 09/29/2026 | Gilbert Cisneros CA31 | Partial sale | $1,001 - $15,000 | 10/12/2026 filing |
| 05/11/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 6/8/2026 filing |
| 04/29/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 5/8/2026 filing |
| 03/19/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 4/7/2026 filing |
| 03/18/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 4/7/2026 filing |
| 03/03/2026 | Gilbert Cisneros CA31 | Purchase | $1,001 - $15,000 | 4/7/2026 filing |
Disclosed under the STOCK Act. Amounts are the ranges the law requires, filings can lag a trade by up to 45 days, and a disclosure is not evidence of wrongdoing. All congressional trades ›
Other companies
Price and key figures from Nasdaq's public quote data, refreshed through the day; the chart is live from TradingView; options activity, ratings, financials, earnings and filings refreshed through the day. Congressional trades parsed from official House filings. Market information, not investment advice.
